Clinical trials: Prostatic Disease
Recurrent Prostate Cancer
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
This randomized phase II trial is studying how well pazopanib hydrochloride works after leuprolide or goserelin in treating patients with relapsed prostate cancer.
- Trial name
- NCT00454571
- Testing
- pazopanib hydrochloride, leuprolide acetate, goserelin acetate
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enrollment in this study was discontinued by the Sponsor on 01 Dec 2023.
- Trial name
- NCT05605964
- Testing
- Relugolix, Leuprolide Acetate
- Where
- 108 sites in United States
- Volunteers
- 387 people
- Sponsor
- Sumitomo Pharma America, Inc.
Prostate Cancer, Oligometastases
Stereotactic Body Radiation for Prostate Oligometastases
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
- Trial name
- ORIOLE (NCT02680587)
- Testing
- SBRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study.
- Trial name
- mCRPC (NCT01338012)
- Testing
- sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dendreon
Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00337077
- Testing
- eribulin mesylate
- Where
- 147 sites in United States
- Volunteers
- 121 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of eflornithine (DMFO) may be an effective way to prevent the development of prostate cancer.
- Trial name
- NCT00006101
- Testing
- eflornithine
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Thomas E. Ahlering
Neoplasms, Prostate
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at…
- Trial name
- REDUCE (NCT00056407)
- Testing
- Dutasteride
- Where
- 932 sites in United States, Argentina and 40 more
- Volunteers
- 8,231 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population.
- Trial name
- NCT02643667
- Testing
- Ibrutinib, Radical prostatectomy
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
Vitamin D promotes the differentiation of prostate cancer cells and maintains the differentiated phenotype of prostate epithelial cells.
- Trial name
- VD3PCa (NCT01759771)
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Phase I dose escalation study with combination of 177Lu-J591 and 177Lu-PSMA-617 using a dose-fractionated regimen will be performed in patients with documented progressive metastatic CRPC.
- Trial name
- NCT03545165
- Testing
- 177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 in BCR
The current study aimed at evaluating the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Trial name
- GuidePath (NCT04838613)
- Testing
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Prostate Cancer
Effect of Weight Loss on Prostate Cancer Pathology
The purpose of this study is to determine if weight loss prior to radical prostatectomy effects chemical substances in the blood stream and prostate tissue that may affect prostate cancer development and progression.
- Trial name
- NCT00475982
- Testing
- Weight Loss, No Weight Loss Group
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Silibinin has demonstrated anti-cancer activity in the laboratory for several different cancer types, including prostate cancer. Silibinin was originally obtained from milk thistle.
- Trial name
- NCT00487721
- Testing
- Silibin-Phytosome
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Benign Prostatic Hyperplasia
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00894517
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Allergan
Prostatic Neoplasms
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free…
- Trial name
- NCT04523207
- Testing
- Apalutamide, ADT, Relugolix
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Benign Prostatic Hyperplasia (BPH)
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224107
- Testing
- Silodosin
- Where
- 43 sites in United States
- Volunteers
- 461 people
- Sponsor
- Watson Pharmaceuticals
Prostate Cancer
Focal Prostate Radio-Frequency Ablation
The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.
- Trial name
- NCT02328807
- Testing
- Radio-Frequency Ablation (RFA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months…
- Trial name
- NCT00669162
- Testing
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.